Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT02612298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02612298
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02612298. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2018-09-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
Acronym
ESAHOM
Condition
Essential Hypertension
Intervention (Drug)
Arotinolol Hydrochloride
Intervention (Drug)
Metoprolol succinate sustained-release tablet
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02612298
Content hash
e8c9d5a5dd9969016dcc100ebaea78ef217ac674f319ee65c2395ef15b9dec8d